Non Alcoholic steatohepatitis

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported topline results from Part 1 of Phase 1b AVIATION Trial of TERN-201 for treating patients with non-alcoholic steatohepatitis (NASH).   Part 1 of the AVIATION Trial met the primary safety endpoint. Compared to placebo, 10 mg...

89bio Inc (NASDAQ: ETNB) announced topline results from a cohort of 20 patients (Cohort 7) in the Phase 1b/2a proof-of-concept study evaluating pegozafermin (formerly BIO89-100) for nonalcoholic steatohepatitis (NASH). The results show that 63% of patients achieved a two-point or...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has withdrawn its European marketing application seeking approval for obeticholic acid (OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH). The initial application was filed in December 2019 was supported by the interim...

Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac repolarization was conducted under FDA in Phase 1 double-blind clinical trial to be...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead would get an...

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from a Phase 1 trial of TERN-501, a thyroid hormone receptor beta (THR-β) agonist, for NASH. TERN-501 was generally safe and well-tolerated in the SAD and MAD cohorts with a similar incidence of adverse events (...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of Aramchol in NASH and liver fibrosis stage 1 3 patients.  Galmed previously announced a substantial effect on ...

Metacrine Inc (NASDAQ: MTCR) reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly And Co's (NYSE: LLY) Jardiance (empagliflozin) in type 2 diabetes and non-alcoholic steatohepatitis (NASH).   LDL-cholesterol increases with...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.  ARMOR is assessing the evaluate the safety and efficacy of Aramchol for the treatment of...

Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH). The trial will assess lanifibranor combined with Eli Lilly And Co's (NYSE: LLY)...

Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last for months following recovery from the infection. The treatment prospect will be compared against placebo in about 40...

After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH). Instead, Enanta now plans to prioritize combination approaches through out-licensing arrangements....

The FDA has decided that the Fast Track designation previously granted to Inventiva SA's (NASDAQ: IVA) lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis. The decision follows a Fast Track designation request for lanifibranor in NASH with...

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial. Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study. The 43-subject trial was designed to investigate CRV431 at doses of 75 mg (n=12), and 225...

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial. Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of...